Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals develops DNA medicines to treat and protect against diseases associated with HPV, cancer, and infectious diseases. Its products include VGX-3100, INO-3107, INO-3112, INO-5401, INO-4201, INO-4800, and INO-6160, all in various stages of clinical trials. The company has partnered with numerous organizations, including government agencies, foundations, and biopharmaceutical companies. Inovio was incorporated in 1983 and is headquartered in Pennsylvania.
Overview
Strengths
- Conservative leverage: net debt is only 0.4x EBITDA.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 11.8% in each of the last 6 years.
- Our discounted cash flow model finds no value to support the current price: free cash flow is negative.
- Shareholder dilution: the share count has grown by 48.4% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
- Unstable profitability: operating margin ranged from -132,871% to -1,674% over the last 6 years, with operating losses in 6 of them.
Key Financial Data